These findings highlight that targeting the ceRNA network through a combination of E7449 and dupilumab could offer a promising clinical approach to treat LUADBM by modulating key components such as NPRL3 and IL4R, thereby suppressing tumor progression and bone metastasis. Here, IL4R is linked to neoplasm.